Trials / Recruiting
RecruitingNCT06310902
Single-cell Sequencing Analysis of Resectable/Borderline Resectable Pancreatic Cancer Patients
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 40 (estimated)
- Sponsor
- Fujian Medical University Union Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Preoperative neoadjuvant chemotherapy is widely used in treating patients with borderline resectable pancreatic cancer (BRPC). However, there are limitations in this field. Treatment strategies and definitions for BRPC patients differ, and the efficacy and prognosis of neoadjuvant chemotherapy vary greatly.This study aims to utilize single-cell sequencing technology to investigate in-depth the composition and interactions of the tumor microenvironment in patients from the surgical-only group and the preoperative neoadjuvant chemotherapy group.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Single-cell Sequencing Analysis | Identification of rare cell populations, the characterization of cell types and subtypes, and the discovery of novel cell states. |
Timeline
- Start date
- 2024-03-01
- Primary completion
- 2026-03-01
- Completion
- 2026-09-01
- First posted
- 2024-03-15
- Last updated
- 2024-03-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06310902. Inclusion in this directory is not an endorsement.